Search Results - Provencher, L.

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

    Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer by Miles, D., de haas, S., Dirix, L., Romieu, G., Chan, Arlene, Pivot, X., Tomczak, P., Provencher, L., Cortes, J., Delmar, P., Scherer, S.

    Published 2013
    Get full text
  2. 2
    Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

    Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic brea... by Miles, D., Chan, Arlene, Dirix, L., Cortés, J., Pivot, X., Tomczak, P., Delozier, T., Sohn, J., Provencher, L., Puglisi, F., Harbeck, N., Steger, G., Schneeweiss, A., Wardley, A., Chlistalla, A., Romieu, G.

    Published 2010
    Get full text
  3. 3
    Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epiderman growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial

    Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epiderman growth factor receptor 2-normal,... by Eiermann, W., Pienkowski, T., Crown, J., Sadeghi, S., Chan, Arlene, Saleh, M., Sehdev, S., Provencher, L., Semiglazov, V., Press, M., Sauter, G., Lindsay, M., Riva, A., Buyse, M., Drevot, P., Taupin, H., Mackey, J.

    Published 2011
    Get full text
  4. 4
    Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.

    Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized tr... by Mackey, J., Pienkowski, T., Crown, J., Sadeghi, S., Martin, M., Chan, Arlene, Saleh, M., Sehdev, S., Provencher, L., Semiglazov, V., Press, M., Sauter, G., Lindsay, M., Houé, V., Buyse, M., Drevot, P., Hitier, S., Bensfia, S., Eiermann, W., Translational Research In Oncology (TRIO)/ Breast Cancer International Research Group (BCIRG)-005 in

    Published 2016
    Get full text

Search Tools: